Get the Stockscreener App
0.00
100.00%
-129.46
After Hours:
129.50
129.50
+
Blueprint Medicines Corp stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
See More
Previous Close:
$129.46
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$8.35B
Revenue:
$562.12M
Net Income/Loss:
$-155.73M
P/E Ratio:
0.00
EPS:
-2.4613
Net Cash Flow:
$-150.91M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$129.65
Blueprint Medicines Corp Stock (BPMC) Company Profile
Name
Blueprint Medicines Corp
Sector
Industry
Phone
617-374-7580
Address
45 SIDNEY STREET, CAMBRIDGE, MA
Compare BPMC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
0.00 | 8.35B | 562.12M | -155.73M | -150.91M | -2.4613 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-02-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-25 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-18-25 | Initiated | Wolfe Research | Outperform |
| Mar-17-25 | Initiated | Jefferies | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-14-24 | Initiated | JP Morgan | Overweight |
| Oct-24-24 | Initiated | UBS | Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| May-06-24 | Upgrade | Leerink Partners | Underperform → Market Perform |
| Oct-27-23 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-21-23 | Reiterated | Needham | Buy |
| Jul-31-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jun-05-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Jan-03-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Dec-14-22 | Initiated | Needham | Buy |
| Nov-02-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-14-22 | Initiated | Berenberg | Buy |
| Jul-08-22 | Initiated | Oppenheimer | Outperform |
| Jun-27-22 | Initiated | Wells Fargo | Underweight |
| Jun-10-22 | Downgrade | Citigroup | Neutral → Sell |
| Jun-01-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-01-22 | Initiated | Citigroup | Neutral |
| Feb-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-25-22 | Upgrade | Stifel | Hold → Buy |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-30-21 | Resumed | Stifel | Hold |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Hold |
| Nov-02-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-02-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-30-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
| May-05-20 | Initiated | Barclays | Equal Weight |
| Mar-17-20 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Nov-06-19 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-22-19 | Initiated | JMP Securities | Mkt Outperform |
| Oct-03-19 | Initiated | H.C. Wainwright | Buy |
| Sep-12-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-29-19 | Initiated | Piper Jaffray | Neutral |
| Aug-15-19 | Resumed | Raymond James | Mkt Perform |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| May-23-19 | Resumed | Goldman | Buy |
| Apr-03-19 | Initiated | Morgan Stanley | Overweight |
| Sep-25-18 | Initiated | Leerink Partners | Outperform |
| Dec-11-17 | Reiterated | Goldman | Buy |
View All
Blueprint Medicines Corp Stock (BPMC) Latest News
Blueprint Medicines director Jeffrey Albers sells shares for $1.66 million - MSN
Blueprint Medicines, a Sanofi Company, Highlights Long-Term Clinical Benefit of AYVAKIT® (avapritinib) Across Indolent and Advanced Systemic Mastocytosis at 2025 ASH Annual Meeting - Yahoo Finance
Can Blueprint Medicines Corporation (2L9) stock double in coming yearsJuly 2025 Volume & Low Drawdown Investment Ideas - Newser
Is Blueprint Medicines Corporation (2L9) stock ideal for retirement investorsWeekly Loss Report & Weekly Sector Rotation Insights - Newser
Why Blueprint Medicines Corporation stock remains on watchlistsJuly 2025 Momentum & Free High Return Stock Watch Alerts - Newser
Is Blueprint Medicines Corporation (2L9) stock a good hedge against inflation2025 Macro Impact & Free Safe Entry Trade Signal Reports - Newser
Will Blueprint Medicines Corporation (2L9) stock see valuation expansionBull Run & Technical Confirmation Trade Alerts - Newser
Will Blueprint Medicines Corporation stock benefit from automationVolume Spike & Technical Buy Zone Confirmations - moha.gov.vn
How Blueprint Medicines Corporation (2L9) stock compares with tech leadersJuly 2025 Weekly Recap & Free Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Blueprint Medicines patents new CDK4 degradation inducers - BioWorld MedTech
CG Oncology (NASDAQ: CGON) names Rossi to board amid BLA initiation - Stock Titan
What makes Blueprint Medicines Corporation stock attractive to growth funds2025 Biggest Moves & AI Powered Buy and Sell Recommendations - newser.com
What dividend safety rating applies to Blueprint Medicines Corporation (2L9) stock2025 Price Action Summary & Reliable Price Breakout Alerts - newser.com
Why Blueprint Medicines Corporation (2L9) stock remains stable2025 Stock Rankings & Reliable Trade Execution Plans - newser.com
How strong is Blueprint Medicines Corporation (2L9) stock earnings growth2025 EndofYear Setup & Safe Capital Allocation Plans - newser.com
Can momentum traders help lift Blueprint Medicines CorporationEarnings Growth Summary & Free Expert Approved Momentum Trade Ideas - newser.com
What the charts say about Blueprint Medicines Corporation todayJuly 2025 Action & Target Return Focused Picks - newser.com
How Blueprint Medicines Corporation stock reacts to bond yieldsJuly 2025 PostEarnings & Consistent Profit Focused Trading Strategies - newser.com
Will Blueprint Medicines Corporation stock continue upward momentumJuly 2025 Momentum & Safe Investment Capital Preservation Plans - newser.com
Is Blueprint Medicines Corporation stock a good choice for value investors2025 Support & Resistance & Free Real-Time Market Sentiment Alerts - Fundação Cultural do Pará
What catalysts could drive Blueprint Medicines Corporation stock higherMarket Growth Review & Fast Exit and Entry Trade Guides - newser.com
How geopolitical tensions affect Blueprint Medicines Corporation stockFed Meeting & High Accuracy Swing Entry Alerts - newser.com
Sanofi to buy Blueprint Medicines for $9.1B - MSN
Blueprint Medicines CorporationCommon Stock (NQ: BPMC - Markets Financial Content
Is Blueprint Medicines Corporation (2L9) stock a contrarian opportunityEarnings Overview Report & Weekly Breakout Watchlists - newser.com
Will Blueprint Medicines Corporation stock remain a Wall Street favorite - newser.com
Blueprint Medicines Corporation stock volume spike explainedExit Point & Stepwise Trade Signal Guides - newser.com
How Blueprint Medicines Corporation stock benefits from global expansion2025 Technical Overview & Low Drawdown Trading Strategies - newser.com
Will Blueprint Medicines Corporation stock split again soonWeekly Volume Report & Real-Time Volume Analysis Alerts - newser.com
Blueprint Medicines Corp Stock (BPMC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):